FDA - Spark Newswire

5 minute read

Alkermes Says Presents New Data On Nemvaleukin Alfa At 2021 ASCO Meeting

June 4, 9:19 AM

Alkermes plc (NASDAQ:ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2)

ALKS

3 minute read

FDA
News

Puma Biotech Highlights Presentation Of Data From Phase 3 ExteNET Trial In Early Stage HER2-Positive Breast Cancer Patients At American Society Of Clinical Oncology

By Benzinga Newsdesk

June 4, 9:17 AM

Results show improved outcomes in overall survival in patients with HER2-positive early stage breast cancer who received ≥ 11 months of treatment with neratinib LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc.

PBYI

3 minute read

FDA
News

Puma Biotech Highlights Presentation Of Data Comparing Findings From Phase 2 CONTROL Trial With Neratinib Arm Of Phase 3 ExteNET Trial At American Society of Clinical Oncology

By Benzinga Newsdesk

June 4, 9:14 AM

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the Phase II CONTROL trial with

PBYI

3 minute read

Agenus Says Co’s Presentations At ASCO 2021 ‘Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373’

By Benzinga Newsdesk

June 4, 9:14 AM

Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections,

AGEN

6 minute read

BeiGene Presents Clinical Data From 2 Phase 2 Trials Of Pamiparib At 2021 ASCO Meeting

By Benzinga Newsdesk

June 4, 9:09 AM

Pamiparib, a potent and selective PARP1 and PARP2 inhibitor, demonstrated meaningful and durable efficacy in patients with advanced HER2-negative breast cancer Pamiparib showed numerically higher progression-free

BGNE

2 minute read

FDA
News

Y-mAbs Highlights Frontline Data For DANYELZA In High-Risk Neuroblastoma To Be Presented At American Society of Clinical Oncology Jun. 4

By Benzinga Newsdesk

June 4, 9:09 AM

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based

YMAB

3 minute read

Allogene Therapeutics Highlights Phase 1 Data On ALLO-501 And ALLO-501A In Relapsed/Refractory Non-Hodgkin Lymphoma At 2021 ASCO Meeting

By Benzinga Newsdesk

June 4, 9:09 AM

ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from

ALLO

2 minute read

FDA
News

Athenex Highlights Data For 2 Poster Presentations At American Society Of Clinical Oncology

By Benzinga Newsdesk

June 4, 9:08 AM

Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel Post-hoc subgroup efficacy analysis based on updated tumor subtypes in the oral

ATNX

4 minute read

FDA
News

AbbVie Offers Extended Long-Term Data From Phase 3 Study Of IMBRUVICA vs Chlorambucil For Patents With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma At American Society Of Clinical Oncology Jun. 4

By Benzinga Newsdesk

June 4, 9:07 AM

With up to seven years of data, progression-free and overall survival benefits continue to be observed with first-line single-agent IMBRUVICA treatment in CLL patients including selected patients with or without

ABBV

2 minute read

TRACON Pharmaceuticals Presents Data From Phase 1 Study Of Uliledlimab (TJ004309) And Tecentriq (Atezolizumab) At ASCO Meeting

By Benzinga Newsdesk

June 4, 9:06 AM

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the

TCON